O	0	9	Radiation
O	9	10	-
O	10	17	related
O	18	25	quality
O	26	28	of
O	29	33	life
O	34	44	parameters
O	45	50	after
B-intervention	51	59	targeted
I-intervention	60	74	intraoperative
I-intervention	75	87	radiotherapy
O	88	94	versus
B-control	95	100	whole
I-control	101	107	breast
I-control	108	120	radiotherapy
O	121	123	in
O	124	132	patients
O	133	137	with
O	138	144	breast
O	145	151	cancer
O	151	152	:
O	153	160	results
O	161	165	from
O	166	169	the
O	170	180	randomized
O	181	186	phase
O	187	190	III
O	191	196	trial
O	197	203	TARGIT
O	203	204	-
O	204	205	A
O	205	206	.

O	207	221	Intraoperative
O	222	234	radiotherapy
O	235	236	(
O	236	240	IORT
O	240	241	)
O	242	244	is
O	245	246	a
O	247	250	new
O	251	260	treatment
O	261	269	approach
O	270	273	for
O	274	279	early
O	280	285	stage
O	286	292	breast
O	293	299	cancer
O	299	300	.

O	301	305	This
O	306	311	study
O	312	319	reports
O	320	322	on
O	323	326	the
O	327	334	effects
O	335	337	of
O	338	342	IORT
O	343	345	on
O	346	355	radiation
O	355	356	-
O	356	363	related
O	364	371	quality
O	372	374	of
O	375	379	life
O	380	381	(
O	381	384	QoL
O	384	385	)
O	386	396	parameters
O	396	397	.

B-total-participants	398	401	Two
I-total-participants	402	409	hundred
I-total-participants	410	413	and
I-total-participants	414	420	thirty
B-eligibility	421	426	women
I-eligibility	427	431	with
I-eligibility	432	437	stage
I-eligibility	438	439	I
I-eligibility	439	440	-
I-eligibility	440	443	III
I-eligibility	444	450	breast
I-eligibility	451	457	cancer
O	458	459	(
O	459	462	age
O	462	463	,
B-age	464	466	31
I-age	467	469	to
I-age	470	472	84
I-age	473	478	years
O	478	479	)
O	480	484	were
O	485	492	entered
O	493	497	into
O	498	501	the
O	502	507	study
O	507	508	.

O	509	510	A
O	511	517	single
O	517	518	-
O	518	524	center
O	525	533	subgroup
O	534	536	of
B-total-participants	537	539	87
O	540	545	women
O	546	550	from
O	551	554	the
O	555	558	two
O	559	563	arms
O	564	566	of
O	567	570	the
O	571	581	randomized
O	582	587	phase
O	588	591	III
O	592	597	trial
O	598	604	TARGIT
O	604	605	-
O	605	606	A
O	607	608	(
O	608	616	TARGeted
O	617	622	Intra
O	622	623	-
O	623	632	operative
O	633	645	radioTherapy
O	646	652	versus
O	653	658	whole
O	659	665	breast
O	666	678	radiotherapy
O	679	682	for
O	683	689	breast
O	690	696	cancer
O	696	697	)
O	698	701	was
O	702	710	analyzed
O	710	711	.

O	712	723	Furthermore
O	723	724	,
O	725	732	results
O	733	737	were
O	738	746	compared
O	747	749	to
O	750	753	non
O	753	754	-
O	754	764	randomized
O	765	772	control
O	773	779	groups
O	779	780	:
O	781	782	n
O	783	784	=
B-intervention-participants	785	787	90
O	788	797	receiving
O	798	802	IORT
O	803	805	as
O	806	807	a
O	808	813	tumor
O	814	817	bed
O	818	823	boost
O	824	832	followed
O	833	835	by
O	836	844	external
O	845	849	beam
O	850	855	whole
O	856	862	breast
O	863	875	radiotherapy
O	876	877	(
O	877	881	EBRT
O	881	882	)
O	883	890	outside
O	891	893	of
O	894	900	TARGIT
O	900	901	-
O	901	902	A
O	903	904	(
O	904	908	IORT
O	908	909	-
O	909	914	boost
O	914	915	)
O	915	916	,
O	917	920	and
O	921	922	n
O	923	924	=
B-control-participants	925	927	53
O	928	935	treated
O	936	940	with
O	941	945	EBRT
O	946	954	followed
O	955	957	by
O	958	960	an
O	961	969	external
O	969	970	-
O	970	974	beam
O	975	980	boost
O	981	982	(
O	982	986	EBRT
O	986	987	-
O	987	992	boost
O	992	993	)
O	993	994	.

O	995	998	QoL
O	999	1002	was
O	1003	1012	collected
O	1013	1018	using
O	1019	1022	the
O	1023	1031	European
O	1032	1044	Organization
O	1045	1048	for
O	1049	1057	Research
O	1058	1061	and
O	1062	1071	Treatment
O	1072	1074	of
O	1075	1081	Cancer
O	1082	1089	Quality
O	1090	1092	of
O	1093	1097	Life
O	1098	1112	Questionnaires
O	1113	1116	C30
O	1117	1118	(
O	1118	1121	QLQ
O	1121	1122	-
O	1122	1125	C30
O	1125	1126	)
O	1127	1130	and
O	1131	1135	BR23
O	1136	1137	(
O	1137	1140	QLQ
O	1140	1141	-
O	1141	1145	BR23
O	1145	1146	)
O	1146	1147	.

O	1148	1151	The
B-outcome	1152	1156	mean
I-outcome	1157	1163	follow
I-outcome	1163	1164	-
I-outcome	1164	1166	up
I-outcome	1167	1173	period
O	1174	1176	in
O	1177	1180	the
O	1181	1187	TARGIT
O	1187	1188	-
O	1188	1189	A
O	1190	1196	groups
O	1197	1200	was
B-iv-cont-mean	1201	1203	32
O	1204	1210	versus
B-cv-cont-mean	1211	1213	39
I-cv-cont-mean	1214	1220	months
O	1221	1223	in
O	1224	1227	the
O	1228	1231	non
O	1231	1232	-
O	1232	1242	randomized
O	1243	1250	control
O	1251	1257	groups
O	1257	1258	.

O	1259	1267	Patients
O	1268	1277	receiving
O	1278	1282	IORT
O	1283	1288	alone
O	1289	1297	reported
O	1298	1302	less
O	1303	1310	general
B-outcome	1311	1315	pain
O	1316	1317	(
B-iv-cont-mean	1317	1319	21
I-iv-cont-mean	1319	1320	.
I-iv-cont-mean	1320	1321	3
I-iv-cont-mean	1322	1328	points
O	1328	1329	)
O	1329	1330	,
B-outcome	1331	1337	breast
O	1338	1339	(
B-iv-cont-mean	1339	1340	7
I-iv-cont-mean	1340	1341	.
I-iv-cont-mean	1341	1342	0
I-iv-cont-mean	1343	1349	points
O	1349	1350	)
O	1351	1354	and
B-outcome	1355	1358	arm
O	1359	1360	(
B-iv-cont-mean	1360	1362	15
I-iv-cont-mean	1362	1363	.
I-iv-cont-mean	1363	1364	1
I-iv-cont-mean	1365	1371	points
O	1371	1372	)
O	1373	1381	symptoms
O	1381	1382	,
O	1383	1386	and
O	1387	1393	better
B-outcome	1394	1398	role
I-outcome	1399	1410	functioning
O	1411	1412	(
B-iv-cont-mean	1412	1414	78
I-iv-cont-mean	1414	1415	.
I-iv-cont-mean	1415	1416	7
I-iv-cont-mean	1417	1423	points
O	1423	1424	)
O	1425	1427	as
O	1428	1436	patients
O	1437	1446	receiving
O	1447	1451	EBRT
O	1452	1453	(
B-cv-cont-mean	1453	1455	40
I-cv-cont-mean	1455	1456	.
I-cv-cont-mean	1456	1457	9
O	1457	1458	;
B-cv-cont-mean	1459	1461	19
I-cv-cont-mean	1461	1462	.
I-cv-cont-mean	1462	1463	0
O	1463	1464	;
B-cv-cont-mean	1465	1467	32
I-cv-cont-mean	1467	1468	.
I-cv-cont-mean	1468	1469	8
O	1469	1470	;
O	1471	1474	and
B-cv-cont-mean	1475	1477	60
I-cv-cont-mean	1477	1478	.
I-cv-cont-mean	1478	1479	5
I-cv-cont-mean	1480	1486	points
O	1486	1487	,
O	1488	1500	respectively
O	1500	1501	,
O	1502	1503	P
O	1504	1505	<
O	1506	1507	0
O	1507	1508	.
O	1508	1510	01
O	1510	1511	)
O	1511	1512	.

O	1513	1521	Patients
O	1522	1531	receiving
O	1532	1536	IORT
O	1537	1542	alone
O	1543	1547	also
O	1548	1551	had
O	1552	1557	fewer
B-outcome	1558	1564	breast
I-outcome	1565	1573	symptoms
O	1574	1578	than
O	1579	1585	TARGIT
O	1585	1586	-
O	1586	1587	A
O	1588	1596	patients
O	1597	1606	receiving
O	1607	1611	IORT
O	1612	1620	followed
O	1621	1623	by
O	1624	1628	EBRT
O	1629	1632	for
O	1633	1637	high
O	1638	1642	risk
O	1643	1651	features
O	1652	1654	on
O	1655	1660	final
O	1661	1670	pathology
O	1671	1672	(
O	1672	1676	IORT
O	1676	1677	-
O	1677	1681	EBRT
O	1681	1682	;
B-iv-cont-mean	1683	1684	7
I-iv-cont-mean	1684	1685	.
I-iv-cont-mean	1685	1686	0
O	1687	1693	versus
B-cv-cont-mean	1694	1696	29
I-cv-cont-mean	1696	1697	.
I-cv-cont-mean	1697	1698	7
I-cv-cont-mean	1699	1705	points
O	1705	1706	,
O	1707	1708	P
O	1709	1710	<
O	1711	1712	0
O	1712	1713	.
O	1713	1715	01
O	1715	1716	)
O	1716	1717	.

O	1718	1723	There
O	1724	1728	were
O	1729	1731	no
O	1732	1743	significant
O	1744	1755	differences
O	1756	1763	between
O	1764	1770	TARGIT
O	1770	1771	-
O	1771	1772	A
O	1773	1781	patients
O	1782	1791	receiving
O	1792	1796	IORT
O	1796	1797	-
O	1797	1801	EBRT
O	1802	1810	compared
O	1811	1813	to
O	1814	1817	non
O	1817	1818	-
O	1818	1828	randomized
O	1829	1833	IORT
O	1833	1834	-
O	1834	1839	boost
O	1840	1842	or
O	1843	1847	EBRT
O	1847	1848	-
O	1848	1853	boost
O	1854	1862	patients
O	1863	1866	and
O	1867	1875	patients
O	1876	1885	receiving
O	1886	1890	EBRT
O	1891	1898	without
O	1899	1900	a
O	1901	1906	boost
O	1906	1907	.

O	1908	1910	In
O	1911	1914	the
O	1915	1925	randomized
O	1926	1933	setting
O	1933	1934	,
O	1935	1944	important
O	1945	1954	radiation
O	1954	1955	-
O	1955	1962	related
O	1963	1966	QoL
O	1967	1977	parameters
O	1978	1983	after
O	1984	1988	IORT
O	1989	1993	were
O	1994	2002	superior
O	2003	2005	to
O	2006	2010	EBRT
O	2010	2011	.

O	2012	2015	Non
O	2015	2016	-
O	2016	2026	randomized
O	2027	2038	comparisons
O	2039	2045	showed
O	2046	2056	equivalent
O	2057	2067	parameters
O	2068	2070	in
O	2071	2074	the
O	2075	2079	IORT
O	2079	2080	-
O	2080	2084	EBRT
O	2085	2090	group
O	2091	2094	and
O	2095	2098	the
O	2099	2106	control
O	2107	2113	groups
O	2113	2114	.
